iData Insights

Sepsis - Pipeline Review, H2 2015 Now Available at iData Insights

Press Release   •   Dec 01, 2015 16:29 IST

Sepsis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Sepsis - Pipeline Review, H2 2015, provides an overview of the Sepsiss therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sepsis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Browse Complete Report with TOC @

To Get Sample Copy of Report visit @

Table of Contents

Table of Contents

2 List of Tables

6 List of Figures

7 Introduction

8 Global Markets Direct Report Coverage

8 Sepsis Overview

9 Therapeutics Development

10 Pipeline Products for Sepsis - Overview

10 Pipeline Products for Sepsis - Comparative Analysis

11 Sepsis - Therapeutics under Development by Companies

12 Sepsis - Therapeutics under Investigation by Universities/Institutes

17 Sepsis - Pipeline Products Glance

19 Late Stage Products

19 Clinical Stage Products

20 Early Stage Products

21 Unknown Stage Products

22 Sepsis - Products under Development by Companies

23 Sepsis - Products under Investigation by Universities/Institutes

27 Sepsis - Companies Involved in Therapeutics Development

29 Adrenomed AG

29 Altor BioScience Corporation

30 Am-Pharma B.V.

31 Arch Biopartners, Inc.

32 Asahi Kasei Pharma Corp.

33 Biomedica Management Corporation

34 Cell2B S.A.

35 Chiesi Farmaceutici SpA

36 Chiome Bioscience, Inc.

37 Cilian AG

38 Cognosci, Inc.

39 Diomune S.L

40 Endacea, Inc.

41 Evec, Inc.

42 Huons Co., Ltd.

43 Immune Response BioPharma, Inc.

44 Immunethep, SA

45 ImmunNovative Developments SL

46 InflaRx GmbH

47 Integrated BioTherapeutics, Inc.

48 ISU ABXIS Co.,Ltd.

49 Lead Discovery Center GmbH

50 Navigen Pharmaceuticals, Inc.

51 Novadiscovery SAS

52 Ocata Therapeutics, Inc.

53 OncoImmune, Inc.

54 Opsona Therapeutics Limited

55 ProThera Biologics, LLC.

56 Ribomic Inc.

57 Silence Therapeutics Plc

58 Stemedica Cell Technologies, Inc.

59 Syntiron LLC

60 Takeda Pharmaceutical Company Limited

61 TiGenix NV

62 VBS Pharmaceuticals

63 XImmune AB

64 Sepsis - Therapeutics Assessment

65 Assessment by Monotherapy Products

65 Assessment by Target

66 Assessment by Mechanism of Action

68 Assessment by Route of Administration

70 Assessment by Molecule Type

72 Drug Profiles

74 3K3A-APC - Drug Profile

74 7-H9 - Drug Profile

76 AB-022 - Drug Profile

78 AcPepA - Drug Profile

79 adrecizumab - Drug Profile

80 Alpha B Crystalline - Drug Profile

81 ALT-836 - Drug Profile

82 AM/AMBP-1 - Drug Profile

84 Aspidasept - Drug Profile

87 Atu-111 - Drug Profile

88 bacterial sepsis vaccine - Drug Profile

89 BaxB-01 - Drug Profile

90 BaxG-03 - Drug Profile

91 BaxM-159 - Drug Profile

92 BRL-44408 - Drug Profile

93 BTZO-2 - Drug Profile

95 CAR Peptide - Drug Profile

96 ceftaroline fosamil - Drug Profile

97 CN-16 - Drug Profile

99 COG-133 - Drug Profile

100 Cx-611 - Drug Profile

102 Drug for Sepsis - Drug Profile

104 Drugs for Sepsis - Drug Profile

105 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile

106 Drugs to Inhibit Sialidase for Sepsis - Drug Profile

107 Escherichia coli vaccine - Drug Profile

108 EV-007

156 - Drug Profile

109 Glyco-23 - Drug Profile

110 HBN-1 - Drug Profile

111 HBN-3 - Drug Profile

112 HBN-4 - Drug Profile

113 HU-003 - Drug Profile

114 IFX-1 - Drug Profile

115 ImmStem - Drug Profile

116 ImmuneSafe - Drug Profile

117 IND-005 - Drug Profile

119 IND-006 - Drug Profile

120 IR-999 - Drug Profile

121 ISU-201 - Drug Profile

122 Klebsiella pneumoniae vaccine - Drug Profile

123 L-97-1 - Drug Profile

124 LB-1148 - Drug Profile

126 LR-17 - Drug Profile

127 M-33 - Drug Profile

128 meropenem - Drug Profile

129 Mesenchymal Stem Cells - Drug Profile

130 Metablok - Drug Profile 132 Micselon - Drug Profile

133 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile

134 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

135 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

136 Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile

137 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile

138 Nanotherapeutics - Drug Profile

140 NAV-838 - Drug Profile

141 OPN-305 - Drug Profile

143 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile

145 Polysaccharide for Sepsis - Drug Profile

147 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile

148 RBM-005 - Drug Profile

149 Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis - Drug Profile

150 Recombinant Human Alkaline Phosphatase - Drug Profile

151 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile

152 Recombinant Protein for Sepsis - Drug Profile

153 Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile

154 Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile

155 SAN-101 - Drug Profile

156 Slit2N - Drug Profile

157 Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile

159 Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile

160 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile

161 Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile

162 staphylococcus aureus (bivalent) vaccine - Drug Profile

163 Stem Cell Therapy for Autoimmune Diseases - Drug Profile

164 Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile

165 Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile

166 Synthetic Peptides for Infectious Disease - Drug Profile

167 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile

168 Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile

169 Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile

170 TF-0003 - Drug Profile

171 thrombomodulin alfa - Drug Profile

172 TRX-306 - Drug Profile

174 vancomycin hydrochloride - Drug Profile

175 Yersinia pestis vaccine - Drug Profile

176 Sepsis - Recent Pipeline Updates

177 Sepsis - Dormant Projects

188 Sepsis - Discontinued Products

192 Sepsis - Product Development Milestones

193 Featured News & Press Releases

193 Appendix

198 Methodology

198 Coverage

198 Secondary Research

198 Primary Research

198 Expert Panel Validation

198 Contact Us

198 Disclaimer

Read More

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

Contact Us:
iData Insights

Tel: 1-866-237-2965


AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.